Molecular Analysis for Combination Therapy Choice (ComboMATCH)

Protocol: ECOG – EAY191

SCHEMA EAY191

Please Note:  Below is only a partial list of eligibility, please contact the Genesys Hurley Cancer Institute, Research Department at (810) 762-8181, (810) 762-8079 or (810) 762-8038 to discuss full eligibility requirements.  Thank you!

Eligibility:

1. Patient must have measurable disease
2. Patient must have an ECOG performance status between 0-2.
3. Patient must be deemed potentially eligible for a ComboMATCH Treatment Trial as assessed by the enrolling provider.
4. All patients must have sequencing results available from an NCI credentialed Designated Laboratory (DL).
5. Patients must have locally advanced or advanced histologically documented solid tumors requiring therapy and meet one of the following criteria:
   1. Patients must have progressed on at least one line of standard systemic therapy.
   2. Patients whose disease has no standard treatment that has been shown to prolong overall survival.
6. Patients 18 years and older who have tumor amenable to minimal risk image-guided or direct vision biopsy and must be willing and able to undergo a tumor biopsy to obtain samples for research if the patient is to enroll in a ComboMATCH treatment trial. OR Patients 18 years and older who do not have disease that is biopsiable at minimal risk to the patient must
   confirm availability of an archival tumor tissue specimen for submission for research if the patient enrolls to a ComboMATCH Treatment Trial.